Sermorelin + GHRP-6 + GHRP-2
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
This product is a growth-hormone secretagogue blend that combines three peptides in a single vial: sermorelin, GHRP-6, and GHRP-2. Sermorelin is an analog of growth-hormone-releasing hormone (GHRH), while GHRP-6 and GHRP-2 belong to a separate class of growth-hormone-releasing peptides (GHRPs) that act on the ghrelin receptor.
The rationale behind the combination is that GHRH analogs and GHRPs stimulate the pituitary through two distinct pathways. Pairing them is studied for its potential to produce a larger, more pulsatile release of growth hormone (GH) than either component achieves on its own.
Human clinical data on these compounds is limited, and this specific three-peptide combination is not an approved formulation. It is sold for research purposes only.
How it works
Sermorelin mimics endogenous GHRH by binding GHRH receptors on the anterior pituitary, which is thought to trigger the intracellular signaling that drives GH transcription and secretion. GHRP-6 and GHRP-2 act instead as agonists at the ghrelin receptor (GHS-R1a), a separate site that also promotes GH release. In preclinical work, GHRP-2 and GHRP-6 were shown to release GH through the same ghrelin-receptor mechanism despite their structural differences.
Because the GHRH and ghrelin-receptor pathways are complementary, activating both at once is studied for a synergistic effect on GH output. The GHRP components are also commonly reported to stimulate appetite, an effect attributed to their ghrelin-like activity.
Reported benefits
- Studied for stimulating pulsatile growth-hormone release via two parallel pathways
- Reported increases in insulin-like growth factor-1 (IGF-1) with GH secretagogue therapy
- Studied in the context of body composition, lean mass, and recovery
- GHRP components commonly reported to increase appetite
These are reported and studied effects, not guaranteed outcomes.
Considerations & side effects
Because rigorous human trials of this specific blend are lacking, its long-term safety profile is not well characterized. Commonly reported effects of GH secretagogues include injection-site irritation, water retention, tingling or numbness, and increased hunger driven by the GHRP components. Effects on blood glucose and cortisol or prolactin have also been discussed for this class, particularly at higher exposures.
Product purity and the exact ratio of the three peptides vary in the research-chemical market, and a combination vial makes individual dosing harder to control. This information is educational and is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is the Sermorelin + GHRP-6 + GHRP-2 blend?
A combination growth-hormone secretagogue that pairs sermorelin — a GHRH analog — with two ghrelin-receptor agonists, GHRP-6 and GHRP-2. The idea is to stimulate the pituitary through two complementary pathways at once. It is typically sold as a single lyophilized vial.
Why combine a GHRH analog with GHRPs?
Sermorelin and the GHRPs act on different receptors. Combining them is studied for a potentially larger, more synergistic release of growth hormone than either mechanism produces alone.
Is this blend FDA-approved?
No. This combination is not approved by the FDA or any major regulator for human therapeutic use and is sold for research purposes only. Sermorelin has been marketed as an individual prescription product in the past, but this multi-component blend is not an approved formulation.
What is the difference between GHRP-6 and GHRP-2?
Both are ghrelin-receptor agonists that trigger GH release. GHRP-2 is generally associated with a stronger GH response, while GHRP-6 is more strongly linked to appetite stimulation. Both can increase hunger.
How is it typically administered?
Most commonly by subcutaneous injection after reconstitution with bacteriostatic water. All three components are peptides delivered together from the same vial.
References
- Cheng J, et al. Growth hormone releasing peptides: a comparison of the GH-releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells. ↗
- Sigalos JT, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. ↗
- Laferrère B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. ↗
Related compounds
Triple GH secretagogue blend combining CJC-1295 (no DAC / Mod GRF 1-29) with two ghrelin mimetics, ipamorelin and GHRP-2, for amplified synergistic GH release. Sold as a single 9mg lyophilized vial.
Pre-mixed blend of CJC-1295 (no DAC) and Ipamorelin for synergistic growth hormone release. Classic GH secretagogue combination sold as a single vial.
A synthetic growth-hormone-releasing peptide (ghrelin-receptor agonist) that stimulates pituitary GH secretion via a pathway distinct from GHRH. The original GHRP from which ipamorelin was later derived; typically pulsed subcutaneously, often stacked with a GHRH.